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Nadeen O. Chahine

Abstract Molecular events that drive disc damage and low back pain (LBP) may precede clinical manifestation of
disease onset and can cause detrimental long-term effects such as disability. Biomarkers serve as objective molecular
indicators of pathological processes. The goal of this study is to identify systemic biochemical factors as predictors of
response to treatment of LBP with epidural steroid injection (ESI). Since inflammation plays a pivotal role in LBP, this
pilot study investigates the effect of ESI on systemic levels of 48 inflammatory biochemical factors (cytokines,
chemokines, and growth factors) and examines the relationship between biochemical factor levels and pain or disability in
patients with disc herniation (DH), or other diagnoses (Other Dx) leading to low back pain, which included spinal stenosis
(SS) and degenerative disc disease (DDD). Study participants (n = 16) were recruited from a back pain management
practice. Pain numerical rating score (NRS), Oswestry Disability Index (ODI), and blood samples were collected pre- and
at 7 to 10 days post-treatment. Blood samples were assayed for inflammatory mediators using commercial multiplex
assays. Mediator levels were compared pre- and post-treatment to investigate the potential correlations between clinical
and biochemical outcomes. Our results indicate that a single ESI significantly decreased systemic levels of SCGF-b and IL2. Improvement in pain in all subjects was correlated with changes in chemokines (MCP-1, MIG), hematopoietic progenitor factors (SCGF-b), and factors that participate in angiogenesis/fibrosis (HGF), nociception (SCF, IFN-a2), and
inflammation (IL-6, IL-10, IL-18, TRAIL). Levels of biochemical mediators varied based on diagnosis of LBP, and
changes in pain responses and systemic mediators from pre- to post-treatment were dependent on the diagnosis cohort. In
the DH cohort, levels of IL-17 and VEGF significantly decreased post-treatment. In the Other Dx cohort, levels of IL-2Ra,
IL-3, and SCGF-b significantly decreased post-treatment. In order to determine whether mediator changes were related to
pain, correlations between change in pain scores and change in mediator levels were performed. Subjects with DH
demonstrated a profile signature that implicated hematopoiesis factors (SCGF-b, GM-CSF) in pain response, while subjects
with Other Dx demonstrated a biomarker profile that implicated chemokines (MCP-1, MIG) and angiogenic factors (HGF,
VEGF) in pain response. Our findings provide evidence that systemic biochemical factors in patients with LBP vary by
diagnosis, and pain response to treatment is associated with a unique profile of biochemical responses in each diagnosis
group. Future hypothesis-based studies with larger subject cohorts are warranted to confirm the findings of this pilot
exploratory study.
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Introduction
Up to 84 % of adults have low back pain (LBP) at some
time in their lives [1, 2]. The long-term outcome of LBP is
generally favourable [3], but given the prevalence of LBP,
persistent symptoms affect millions of individuals.
Approximately 5 % of people with LBP disability account
for 75 % of the costs associated with this condition [4].
Multiple treatment options for subacute and chronic LBP
are available, including pharmacologic and non-interventional treatments, non-surgical interventional treatments,
and surgical treatments. Non-surgical interventional treatments, such as epidural steroid injections (ESIs), are generally recommended for patients with LBP who have failed
conservative management.
ESIs have been used for pain control in patients with
radiculopathy due to herniated disc, spinal stenosis, and
non-specific low back pain due to degenerative disc disease. However, the efficacy is unclear, due to heterogeneous populations and specifics of the ESI interventions
in randomized trials. A systematic review of randomized,
placebo-controlled trials found that ESI was associated
with a small improvement in leg pain (6.2 %) and disability (3.1 %) for up to 3 months, but no improvement
at 1 year [5–7]. The trials included heterogeneous groups
of patients in terms of symptom duration, and both
therapeutic and placebo treatments varied considerably
between trials. Despite the relatively small average benefit observed in clinical trials, clinical experience suggests
that some patients do obtain more significant relief,
making it reasonable to offer a trial of ESIs for patients
who have not found pain relief with more conservative
approaches, particularly for patients who are not candidates for surgery or are not interested in surgery. In light
of this, there is a significant need for developing diagnostic tools that are predictive of response to treatment
with ESI.
Molecular events that drive disc damage and LBP may
precede clinical manifestation of disease onset and can
cause detrimental long-term effects such as disability.
Biomarkers serve as objective molecular indicators of
pathological processes. Owing to the heterogeneous aetiologies of back pain, identifying a single biomarker predictive of disc damage would be unlikely. Consequently,
there is great interest in identifying a panel of biomarkers
that could be incorporated into a signature predictive of
symptom or disease progression. For example, a signature
profile of disc destruction could facilitate more informed
clinical decisions and help guide personalized medical
approaches.

The goal of this pilot study is to explore the correlation of
systemic biochemical factors and clinical response to treatment of LBP with ESI. Since inflammation plays a pivotal
role in LBP [8, 9], and endogenous glucocorticoids are antiinflammatory, this study investigates the effect of ESI on
systemic levels of inflammatory biochemical factors (cytokines, chemokines, and growth factors) and examines the
relationship between biochemical factors and pain or disability in patients with LBP due to various aetiologies. The
three aetiologies of LBP included here are: disc herniation
(DH), or other diagnoses such as degenerative disc disease
(DDD), and spinal stenosis (SS). DH is the focal displacement of disc material beyond the limits of the disc space and
can irritate nearby nerves resulting in pain, numbness, or
weakness in the legs. SS is a pathological narrowing of the
spinal canal due to hypertrophy of the ligamentum flavum
and is associated with paresthesia, pain, and symptoms of
neurologic compromise. DDD includes disc pathology such
as desiccation and loss of disc height, diffuse disc bulging,
fissures, osteophytes, or end-plate sclerosis without specific
indication for herniation or stenosis. We hypothesize that
patients responsive to treatment via local delivery of steroids
into the epidural space, as defined by reduction in pain
scores, will exhibit a coordinated change in systemic biochemical factors that may be associated with the ESI treatment. Since ESI treatment is indicated for various causes of
LBP, we investigated levels and heterogeneity of systemic
biochemical factors in differing diagnostic groups.

Methods
Participants
This study was performed with the approval of the IRB of the
North Shore-LIJ Health System. Written informed consent
was obtained from all subjects prior to enrolment. Samples
were obtained from subjects undergoing ESI by a pain management physician for LBP with or without radiculopathy.
Treatment consisted of an interlaminar ESI of 120 mg
methylprednisolone mixed with 2cc of 1 % lidocaine. Patients
were referred for ESI after having failed more conservative
treatments including physical therapy and/or oral antiinflammatory pain medications. According to clinical guidelines, ESI treatment is indicated before a patient is referred for
surgery. Study subjects have reported pain symptoms for a
median duration of 10.5 months (min: 0.25 months, max:
60 months), prior to enrolment in this study.
The following inclusion criteria were used: 18 years of
age or older, requiring interlaminar ESI in the lumbar spine
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region (L1–L2 to L5–S1) for diagnoses including SS, DH,
and DDD. Subjects were excluded if they had: history of
previous lumbar surgery, epidural corticosteroid injection
within the last 6 months, known inflammatory condition
(e.g. rheumatoid arthritis, systemic lupus erythematosus,
gout, osteomyelitis, other infections), history of cancer, and
were pregnant or breastfeeding at time of enrolment.
Blood sample and clinical pain and disability surveys
were obtained prior to epidural injection (pre-treatment)
and at 7–10 days following epidural injection (post-treatment). Whole blood was collected (BD Vacutainer 367874)
and maintained at 4 °C until processing. Blood samples
were centrifuged, aliquoted, and stored at -80 °C until
biochemical analysis. Pain was recorded at each visit using
the numerical rating scale (NRS), an 11-point unidimensional measure of pain intensity ranging from 0 to 10, with
0 representing ‘no pain’ and 10 representing ‘most severe
pain’. Disability was measured using a validated questionnaire (Oswestry Low Back Pain Disability Questionnaire) and was quantified by computing the Oswestry
Disability Index (ODI) at pre- and post-treatment. ODI
values in 0–20 % represent minimal disability, and values
over 80 % represent complete disability. Clinical data such
as basic demographics, underlying diagnosis (DH, SS, or
DDD), prior treatment history, and duration of pain
symptoms, categorized as acute (\6 months) or chronic
([6 months) were obtained from subjects’ medical records.
Biochemical analysis
Systemic plasma levels of 48 mediators were assayed by a
multiplex bead-based assay (Bio-Plex Pro Human Cytokine
27-plex Assay, Group I, #M500KCAF0Y, and Bio-Plex Pro
Human Cytokine 21-plex Assay, Group II, #MFO-005KMII,
Bio-Rad, Hercules, CA) using the Luminex LX100/200
platform and xPONENT software. The assay was performed
according to manufacturer’s recommendations. Samples
were run in duplicate. The factors assayed were: interleukin
(IL)-1 alpha (IL-1a), IL-1b, IL-1 receptor antagonist (IL1ra), IL-2, IL-2 receptor alpha (IL-2Ra), IL-3, IL-4, IL-5, IL6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15,
IL-16, IL-17A, IL-18, cutaneous T cell-attracting chemokine
(CTACK), eotaxin, basic fibroblast growth factor (FGFbasic), granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GMCSF), growth-related protein alpha (GROa), hepatocyte
growth factor (HGF), interferon (IFN) alpha 2 (IFN-a2), IFN
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gamma (IFN-c), C-X-C motif chemokine 10 (IP-10/
CXCL10), leukemia inhibitory factor (LIF), monocyte
chemoattractant protein (MCP-1/CCL2), MCP-3/CCL7,
macrophage colony-stimulating factor (M-CSF), macrophage migration inhibitory factor (MIF), monokine induced
by IFN-gamma (MIG), macrophage inflammatory protein
(MIP)-1 alpha (MIP-1a/CCL3), MIP-1b/CCL4, beta-nerve
growth factor (b-NGF), platelet-derived growth factor subunit B (PDGF-BB), C-C motif chemokine 5 (RANTES/
CCL5), stem cell factor (SCF), stem cell growth factor beta
(SCGF-b), stromal-derived factor alpha (SDF-1a), tumour
necrosis factor (TNF) alpha (TNF-a), TNF beta (TNF-b),
TNF-related apoptosis-inducing ligand (TRAIL), and vascular endothelial growth factor (VEGF). The ranges of each
factor assayed, including upper and lower limits of detection,
were determined. For statistical purposes, values that were
below the range of the assay were extrapolated, and values
that were below the lowest limit of detection were assigned
the value of the lowest limit of detection.
Statistical analysis
Levels of cytokines, chemokines, and growth factors were
compared between pre- and post-treatment in all subjects
using a Wilcoxon signed-rank (WSR) test. Subjects were
grouped by diagnosis, as either disc herniation (DH) or
Other Dx [including spinal stenosis (SS) and degenerative
disc disease (DDD)]. The Mann–Whitney test was used to
compare diagnostic groups (DH vs. Other Dx) with respect
to pre-treatment levels. Differences within diagnosis
cohorts from pre- to post-treatment were examined using
WSR test. Additional analysis was conducted to examine
whether the percent change in pain NRS was correlated
with the percent change in each biochemical factor measurement or ODI. Spearman’s correlation coefficients (q)
and corresponding p values are reported for significant
correlations between the percent change in pain NRS and
percent change in each of the biochemical factor. Spearman’s correlation analysis was performed on all subjects
and separately by diagnosis cohort (DH, Other Dx). All
statistical analyses were generated using SAS with significance level set at a = 0.05. No adjustments were applied
for multiple comparisons because this was a pilot exploratory study. The use of a = 0.05 is acceptable in pilot
studies; however, we recognize that type-I error may be
inflated in the absence of a multiple comparison correction.
In pilot exploratory studies, such as the current one,
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Table 1 Summary of demographics of all study subjects (total) and
by diagnosis groups (DH or Other Dx)
Subject demographics

DH

Other Dx

Total

Number of subjects (N)

10

6

16

Age (years,
mean ± SD)

54 ± 15

57 ± 16

55 ± 15

p
value

0.74

BMI (mean ± SD)

30 ± 7

29 ± 4

30 ± 6

0.96

Male

3 (30 %)

2 (33 %)

5 (31 %)

0.96

Female

7 (70 %)

4 (67 %)

11
(69 %)

Table 2 Summary of clinical measures of pain (NRS) and disability
(ODI) in all subjects (N = 16), in DH subjects (N = 10), and in Other
Dx subjects (N = 6) at pre- and post-treatment
Clinical outcomes

Pretreatment

Posttreatment

p value
(WSR)

Pain NRS (all subjects)

9.3 ± 0.9;

5.2 ± 3.4;

0.00048

10 (9–10)

5 (2.5–8)

Pain NRS (DH)

9.5 ± 0.9;

5.5 ± 2.9;

10 (9–10)

5.5 (2.5–7)

9.0 ± 1.1;

4.8 ± 4.3;

9 (9–10)

4.8 (0–9)

45 ± 15;

34 ± 18;

49 (34–56)

31 (21–52)

44 ± 15;

37 ± 16;

41 (32–52)

38 (26–51)

48 ± 15;

30 ± 22;

54 (48–58)

23 (20–53)

Pain NRS (Other Dx)
ODI (all subjects)
ODI (DH)
ODI (Other Dx)

0.0078
0.13
0.064
0.42
0.094

Data are presented as mean ± standard deviation; median (Q1–Q3),
where Q1 and Q3 are the lower and upper quartiles, respectively

adjustments for multiple testing may not be required and
often may not be practical [10, 11].

Results
Subject characteristics
Levels of systemic mediators in subjects with LBP were
analysed from subjects undergoing ESI (n = 16), due to a
diagnosis of DH (n = 10) or Other Dx, including SS or
DDD (n = 6). Age, gender, and body mass index (BMI)
demographics are presented in Table 1. The mean age of
recruited subjects was 55 ± 15 years. Subjects were 70 %
female and 30 % male, with similar distribution observed
between DH and Other Dx groups. The average BMI was
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30 ± 6 (Table 1). In the DH cohort, five of ten subjects
reported chronic pain (duration of pain symptoms for
6 months or longer). In Other Dx group, five of six subjects
reported chronic pain.
Clinical and biochemical changes from pre- to posttreatment
At pre-treatment, the mean pain NRS was 9.3 ± 0.9, and
the ODI was 45 ± 15 %. At post-treatment, NRS levels
were observed to be 44 % lower than pre-treatment (posttreatment: 5.2 ± 3.4, p \ 0.001, Table 2). A trend for
slightly lower ODI (34 ± 18 %) was also observed posttreatment (Table 2). Across all study subjects, circulating
levels of SCGF-b and IL-2 decreased significantly posttreatment relative to pre-treatment (Fig. 1a, b). We examined the relationship between NRS and SCGF-b or IL-2, to
determine whether changes from baseline to post-treatment
in NRS are associated with corresponding changes in
biochemical factors. We observed a significant correlation
between change in NRS and change in SCGF-b in all
subjects (q = 0.645, p = 0.009, Fig. 1c). However, no
significant correlation between change in IL-2 levels was
found with NRS response (Fig. 1d).
Correlations between NRS and other biochemical factors or ODI were also investigated, to determine whether
multiple factors are coordinately varying with change in
NRS. We found that changes in ODI were not significantly
correlated with changes in NRS (q = 0.176, p = 0.5).
However, changes in NRS were significantly correlated
with changes in the levels of MCP-1, SCF, IFN-a2, MIG,
TRAIL, SCGF-b, IL-6, IL-10, HGF, and IL-18 when
analysed in all subjects (Fig. 2).
Differences in biochemical profiles and response by
diagnosis
Subjects who had LBP due to other diagnoses (SS or DDD,
grouped as Other Dx) had significantly higher levels of
many biochemical factors compared to subjects with LBP
attributed to a DH diagnosis (Fig. 3). Circulating levels of
IL-2, IL-3, IL-8, HGF, IFN-a2, LIF, MCP-3, and TNF-b
were significantly higher in subjects with Other Dx compared to DH (Fig. 3). No significant differences in age,
BMI, or gender were observed between the DH cohort and
the Other Dx cohort.
Changes in pain responses from pre- to post-treatment
were dependent on the diagnosis cohort. In DH cohort, the
average pain NRS was significantly lower post-treatment
versus pre-treatment (Table 2). The NRS in Other Dx was
50 % lower in post- versus pre-treatment, although this was
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Fig. 1 a–b Mediator levels of SCGF-b and IL-2 were significantly
different in pre- versus post-treatment in all subjects (*p \ 0.05, plot
line: median, box: 25–75 % percentiles, error bars: range). c–d
Spearman’s correlations (q and p value) between % change in pain

NRS and % change in SCGF-b and IL-2 in all subjects. A significant
correlation between % change in SCGF-b and % change in NRS was
observed, while % change in IL-2 levels was not significantly
correlated with % change in pain NRS

Fig. 2 Spearman’s correlation coefficient (q) and p value for
significant correlations observed between % change in pain NRS
and % change in systemic mediator levels of MCP-1, SCF, IFN-a2,

MIG, TRAIL, IL-6, IL-10, HGF, and IL-18 in all subjects. Each point
on scatter plot represents one subject, and line represents the
correlation fit
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Fig. 3 Levels of some systemic mediators prior to treatment differed
based on diagnosis. Levels of IL-2, IL-3, IL-8, HGF, IFN-a2, LIF,
MCP-3, and TNF-b, were significantly higher in Other Dx subjects

compared to DH subjects. *p \ 0.05, **p \ 0.01. Plot line represents
the median, plot box represents the 25–75 % percentiles, and error
bars represent the range

not statistically significant (Table 2). Biochemical changes
in response to treatment also varied by diagnosis. In DH, a
significant decrease in levels of IL-17 and VEGF was
observed post-treatment (Fig. 4). In the Other Dx cohort,
levels of IL-2Ra, IL-3, and SCGF-b significantly decreased
post-treatment (Fig. 4).
We investigated potential factors that might be associated with clinical response status in the two diagnosis
cohorts. Each of the 48 biomarkers was individually
examined for a correlation between changes in mediator
level and changes in pain NRS. Figures 1 and 2 show the
mediators found to be correlated when analysing all subjects together, and Table 3 summarizes the list of mediators significantly correlated in the two diagnosis cohorts.
Of the ten factors correlated with clinical responses in all
subjects, four factors were also significantly correlated only
in the DH group (IL-6, IL-10, IL-18, and SCGF-b,
Table 3), while four other factors were significantly correlated only in the Other Dx subjects (MCP-1, HGF, MIG,

and TRAIL, Table 3). Changes in IFN-a2 and SCF were
significantly correlated in both individual diagnoses
cohorts, and when all subjects were analysed as a single
group. Analysis by diagnosis also yielded factors that were
significantly correlated within each diagnosis cohort, but
not when cohorts were combined into a single group (DH:
GM-CSF, IL-2Ra, IL-12p40; Other Dx: IL-1b, IL-1ra, IL9, IL-12, VEGF, Table 3).

Discussion
The goal of this pilot study was to examine systemic biochemical factors in patients undergoing ESI for lumbar disc
disorders in order to explore their utility as predictors of pain
and disability response to treatment of LBP with ESI. Our
results indicate that a single interlaminar ESI in the lumbar
spine significantly decreased circulating levels of SCGF-b
and IL-2. Improvement in pain in all subjects was correlated

123

176

Fig. 4 Levels of mediators that signficantly changed after ESI
treatment by diagnosis. In DH cohort (top row), levels of IL-17 and
VEGF were significantly lower in post- versus pre-treatment. In Other
Dx cohort (bottom row), levels of IL-2Ra, IL-3, and SCGF-b were

with decreases in chemokines (MCP-1, MIG), hematopoietic
progenitor factors (SCGF-b), and factors that participate in
angiogenesis/fibrosis (HGF), nociception (SCF, IFN-a2),
and inflammation (IL-6, IL-10, IL-18, TRAIL). SCGF-b is a
cytokine for primitive hematopoietic progenitor cells. Its
role in pain or disc degeneration is unknown, although
recently it has been associated with neuroinflammatory
conditions, such as spinal cord injury [12]. To our knowledge, this is the first study to demonstrate that changes in
systemic levels of SCGF-b are positively correlated with
changes in pain levels in patients with low back pain.
We observed additional significant correlations between
changes in pain NRS and biochemical mediators posttreatment. While pain NRS is a commonly used clinical
tool, the NRS is subjective and evaluates only one component of the pain experience, pain intensity, and therefore
does not capture the complexity and idiosyncratic nature of
the pain experience or improvements due to symptom
fluctuations. We observed that changes in systemic biochemical mediators in patients with LBP correlate with
change in NRS after a local epidural space steroid delivery.
Of the factors identified, changes in IFN-a2 and SCF were
correlated with changes in pain NRS independent of
diagnosis. Stem cell factor (SCF) is a neurotrophic factor
for sensory neurons [13]. SCF is a ligand of the c-kit
receptor that is expressed in dorsal root ganglia (DRG)
neurons and in the superficial layer of the spinal cord [14,
15]. Activation of c-kit receptor by SCF in DRGs induces
neurite outgrowth and supports the survival of the c-kit-
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significantly lower in post- versus pre-treatment (*p \ 0.05). Plot line
represents the median, plot box represents the 25–75 % percentiles,
and error bars represent the range

Table 3 Spearman’s correlation coefficient (q) and p value for significant correlations between % change in pain NRS and % change in
systemic mediator levels by diagnosis (DH cohort, Other Dx cohort)
Significantly
correlated in
all subjects
(Figs. 1, 2)

GM-CSF

Significantly
correlated in DH
cohort

Significantly
correlated in Other
Dx cohort

Spearman’s
coefficient
(q)

p
value

Spearman’s
coefficient
(q)

p
value

0.701

0.035

–

NS

HGF

x

–

NS

0.837

0.038

IFN-a2

x

0.773

0.015

0.837

0.038
0.038

IL-1b

–

NS

0.837

IL-1ra

–

NS

0.837

0.038

IL-2Ra

0.748

0.021

–

NS

0.731

0.025

–

NS

–

NS

0.837

0.038

IL-6

x

IL-9
IL-10

x

IL-12
IL-12p40

0.731

0.025

–

NS

–

NS

0.837

0.038
NS

0.840

0.005

–

IL-18

x

0.765

0.016

–

NS

MCP-1
MIG

x
x

–
–

NS
NS

0.956
0.956

0.003
0.003

SCF

x

0.782

0.013

0.837

0.038

SCGF-b

x

0.874

0.002

–

NS

TRAIL

x

–

NS

0.837

0.038

–

NS

0.837

0.038

VEGF

Changes in mediators found to be correlated in all subjects, in DH,
and in Other Dx are marked in italics

Feinstein Institute for Medical Research Immunology (2015) 63:170–180

expressing neurons. Intrathecal injection of SCF induces
mechanical allodynia in mice [16], and SCF activation of
c-kit receptor controls the transduction properties of sensory neurons [17]. Our finding that decreases in SCF levels
are strongly correlated with decrease in pain post-treatment
is consistent with the known role of SCF in nociception.
Interestingly, other factors that promote nerve growth and
pain, such as NGF, were not significantly modulated posttreatment with ESI or with diagnosis.
IFN-a is a family of proteins with immunomodulatory
properties and exerts effects on the neuroendocrine, CNS,
and immune system [18, 19]. IFN-a has a significant
analgesic action in the CNS [18], where in preclinical
studies, the analgesic effects of IFN-a were found to be
related to opioid receptor binding [20–22]. In the current
study, we observed that systemic levels of IFN-a2
decreased significantly with decreasing pain, an effect that
is different from the anti-nociceptive effects of IFN-a is in
the brain. Further studies on the effects of IFN-a2 in the
epidural space and in response to steroid treatment are
warranted to further elucidate its role in spinal pain
mechanisms. Interestingly, the immunoreactivity of
another interferon (IFN-c) was elevated in epidural lavage
of degenerative discs and absent in asymptomatic control
disc lavage [23]. IFN-c immunoreactivity in epidural
lavage is also highly correlated with reported reduction in
pain at 3 months after ESI [24], consistent with this study’s
observation regarding the relationship between systemic
IFN-a2 and pain post-treatment.
Some of the mediators correlated with changes in pain
levels in all subjects are known to participate in pain or
disc aetiology (e.g. MCP-1 and IL-6) [25, 26]. Human disc
tissue is capable of spontaneously producing the chemokine MCP-1 that acts as a chemotactic factor for macrophages and may explain the ingrowth of granulation tissue
seen in DH and resorption [27]. Local production of MCP1 in vivo and in vitro by disc cells from the annulus fibrosis
suggests that annulus cells mediate physiological immunerelated processes during disc degeneration by both autocrine and paracrine signalling [28]. MCP-1 is also elevated
in the blood at the chronic stage of complex regional pain
syndrome [29] and has been proposed as a candidate biomarker that can distinguish between mechanical and
infectious causes of back pain [30]. A correlation in
changes of IL-6 levels and pain levels represents the
complex role of this cytokine in disc diseases and pain. IL6 can be spontaneously produced in vitro by human DH
tissue [31], and IL-6 stimulation of human NP cells inhibits
matrix gene expression and synthesis [32]. In preclinical
models, IL-6 increases production of the pro-inflammatory
cytokine, TNF-a, by neurons in the DRG, and sensitizes
DRG neurons to painful stimuli [33, 34]. In our prior
clinical study, we observed higher levels of IL-6 in subjects
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with LBP relative to controls [35]. Subjects with chronic
lumbar radicular pain have also been shown to have persistent increases in systemic IL-6 [36]. Elevation of IL-6
levels at presentation has been associated with worse outcomes in recovery from DH at 1-year follow-up [37]. Our
current finding that improvement in pain is correlated with
decreases in IL-6 levels further confirms its role in pain
mechanisms. We did not evaluate changes in neuropeptide
Y, a factor recently found to be associated with improvement in pain in elderly individuals with isolated back pain
without radiculopathy [38].
Biochemical profiles of subjects varied by diagnosis;
elevated levels of factors that participate in inflammation
(IL-2, IL-3, IL-8, TNF-b), angiogenesis/fibrosis (HGF),
nociception (IFN-a2, LIF), and chemokines (MCP-3)
were observed in subjects with SS or DDD (Other Dx)
compared to DH subjects. In Other Dx cohort, elevated
systemic cytokine levels may be due to the greater
incidence of chronic pain relative to DH cohort (83 vs.
50 %, respectively). Elevated cytokine levels in Other
Dx are consistent with our prior study that examined
cytokine levels in * 100 subjects with LBP relative to
control subjects [35]. We previously observed that levels
of IL-6 and TNF-a were higher in Other Dx relative to
DH or control subjects [35]. The current study extends
the scope of profiling systemic biochemical factors in
subjects with Other Dx versus DH. Our current findings
of elevated levels of LIF and TNF-b in Other Dx subjects reinforce the well-known roles of the IL-6 and TNF
cytokine families in disc disease and back pain,
respectively.
The biochemical response to treatment also varied based
on diagnoses. Levels of IL-17 and VEGF decreased in DH
subjects post-treatment, whereas IL-2Ra, IL-3, and SCGFb levels decreased in subjects with Other Dx. In DH, IL-17
has been proposed as a potential player in the pathomechanism of degeneration, with a potentially greater contribution from infiltrating inflammatory cells than disc cells
[39–41]. Herniation severity may also modulate the relative
contribution of IL-17 in DH, with greater IL-17
immunoreactive cells found in ruptured DH specimens
than specimens contained within the disc boundary [42].
We did not evaluate changes in mediator levels based on
severity of herniation, though our findings of decreased IL17 levels in DH subjects post-ESI treatment supports the
evidence for its potential role in the pathomechanism. The
known interactions between the IVD and immune system
in DH may promote recovery (i.e. decrease in levels) of
inflammatory mediators post-ESI treatment. Biochemical
responses to treatment may be related to the predisposition
of patients with Other Dx, especially spinal stenosis, to
generally poorer outcomes with respect to ESI treatment
[43] and to higher likelihood of disease progression [44].
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In order to determine whether the changes we observed
in mediators levels from pre- to post-treatment were related
to pain, we performed further analyses to assess potential
correlations between change in pain scores and change in
mediator levels. The factors significantly correlated with
changes in pain (Table 3) did not overlap considerably
with the factors that changed on average from pre- to posttreatment within diagnosis cohorts. For example, IL-3
levels were significantly elevated at pre-treatment in Other
Dx group, and IL-3 levels significantly decreased posttreatment, yet IL-3 levels were not correlated with pain
response in Other Dx cohort (q = -0.119, p = 0.82). We
postulate that mediator-level changes observed in cohort
averages (Fig. 4) may be due to changes in disease condition, response to steroids or epidural intervention, patient
demographic factors, or a combination of all of these
variables. In addition, changes in activity levels of subjects
due to pain relief may add a further level of complexity in
interpreting overall changes in systemic mediators.
In an effort to identify potential predictors of pain
response to treatment, we examined the changes in mediators
with change in pain separately in the DH and Other Dx
cohorts. Each cohort was associated with a unique profile of
factors that were significantly correlated with change in pain.
Loss of pain in Other Dx was correlated with decreases in
chemokines (MCP-1, MIG) and factors that participate in
mechanisms of angiogenesis (HGF, VEGF), inflammation
(IL-1b, IL-1ra, IL-9, IL-12, TRAIL), and nociception (SCF,
IFN-a2). Changes in HGF levels were uniquely correlated
with change in pain in Other Dx, in addition to being significantly higher than in DH at pre-treatment. HGF is an
angiogenic factor that was recently found to slow down the
process of intervertebral disc degeneration by stimulating an
anti-fibrosis process in degenerative discs [45]. Decreases in
nerve degeneration and scar tissue formation around the
sciatic nerve in a constriction injury model have also been
associated with HGF and VEGF [46]. Interestingly, VEGF,
another angiogenic factor, was also significantly correlated
with change in pain in Other Dx group. HGF has known antiinflammatory effects [47] and has been found to mediate
anti-inflammatory effects of platelet-rich plasma (PRP) [48,
49]. Gene therapy with HGF has also been found to provide
long-term symptomatic relief and quality of life improvements in patients with painful diabetic peripheral neuropathy
[50]. Our findings suggest that elevated levels of HGF in
Other Dx may be due to disc angiogenic changes known to
participate in the degenerative cascade [51].
Systemic inflammation is accompanied by changes in
pain perception. We observed significant correlations
between change in pain and levels of the pluripotent proinflammatory cytokine IL-1b, and the receptor antagonist,
IL-1ra, in Other Dx. Elevations of IL-1b in cerebrospinal
fluid have been correlated with pain in a variety of chronic
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painful conditions [52, 53], and locally in osteoarthritis
[54]. IL-1ra is a natural inhibitor of the pro-inflammatory
effects of IL-1b. Decreased levels of IL-1ra have been
observed in patients with pain due to a variety of diseases,
including in local sites of inflammation in patients with
complex regional pain syndrome [55] and in the cerebrospinal fluid of patients with rheumatoid arthritis [56].
Conversely, systemic elevations of IL-1ra were observed
with hyperalgesia in humans with induced systemic
inflammation [57]. These alterations suggest that these
factors have a direct influence on the perception and regulation of pain both in the tissue and in the nervous system.
The correlation between systemic levels of both factors
reinforces the inflammatory mechanism underlying pain,
and the tightly coordinated regulation between IL-1b and
IL-1ra [58, 59].
In DH subjects, improvement in pain was correlated with
decreases in factors that participate in hematopoiesis
(SCGF-b, GM-CSF), nociception (SCF, IFN-a2), and
inflammation (IL-6, IL-10, IL-18, IL-2Ra, IL-12p40). IL-10
is well documented to act as an anti-inflammatory cytokine,
dampening the expression of pro-inflammatory cytokines
and blocking NF-jB activity. IL-10 promoter polymorphisms are associated with increased susceptibility to lumbar disc degeneration [60]. GM-CSF, a hematopoietic
growth factor, also acts on mature myeloid cells and acts as a
pro-inflammatory cytokine [61]. Depletion of GM-CSF can
have profound effects on disease severity and progression in
inflammatory arthritis models [62]. GM-CSF is a key to the
development of osteoarthritis associated pain, and its neutralization can abolish arthritic pain [63]. Our findings on
correlations between pain levels and changes in IL-10 and
GM-CSF are consistent with the factors’ respective roles as
anti-inflammatory and anti-nociceptive factors.
In summary, our pilot study findings indicate that
treatment of LBP subjects with local ESI is associated with
improvement in pain and coordinated decreases in systemic
biochemical factors associated with nociception, inflammation, angiogenesis, chemokines, and hematopoietic
progenitor factors. Factor profiles varied by diagnosis of
LBP, and consequently, changes in systemic biochemical
factors were uniquely correlated in diagnosis cohorts. Two
factors (SCF and IFN-a2) known to participate in nociception were correlated with pain changes independent of
diagnosis, while others were unique to subjects with LBP
due to DH or Other Dx. Subjects with DH demonstrated a
profile that uniquely implicated hematopoiesis factors in
pain response. Subjects with Other Dx demonstrated a
profile that uniquely implicated chemokines and angiogenic factors in pain response.
Some limitations of this pilot study include the relatively small number of subjects especially in the Other Dx
cohort, and an unequal gender distribution, although
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similar gender distributions were observed in both diagnosis cohorts. We recognize that multiple testing increases
the rate of false positives, and therefore, results should be
cautiously interpreted. However, this pilot study was
designed to be an exploratory, hypothesis-generating
endeavour. Therefore, we believe that the precise adjustment of p values is not practical in the context of the goal
of this exploratory study. Future hypothesis-based studies
with larger subject cohorts are warranted to confirm the
findings of this pilot study. We did not evaluate the relationship of disease severity on MRI with biochemical
factors, although our prior study indicated that MRI grade
is neither correlated with nor predictive of biochemical
levels [35]. Similarly, no significant correlation between
the Pfirrmann grade, pain scores, and biochemical markers
was observed in other studies that evaluated the suitability
of a cartilage matrix degradation product as a predictor of
disease severity [64]. Our findings suggest that some of the
variation in clinical outcomes observed in studies or trials
of heterogeneous populations of LBP subjects may be
partly due to heterogeneous biochemical profiles that may
differ by diagnosis. Refinement of inclusion criterion by
diagnosis is warranted in future biomarker studies of LBP.
In addition, future studies will examine longitudinal
changes in biochemical factors in response to ESI in a
larger cohort of LBP subjects.
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